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steroids to children who do not have inflammatory 
changes in the airways. Based upon the findings in 
rats, concerns have been raised that administration 
of inhaled corticosteroids to such patients might 
interfere with normal alveolar development. At 
present there are no data to support this and the risk 
that this would indeed be the case seems very low. 
In clinical practice it is extremely rare that inhaled 
corticosteroids are given to children younger than 6 
months of age. If it is appropropriate at all to base 
risk considerations about inhaled steroids in children 
upon the findings in rats receiving systemic steroids, 
then one would not expect exogenous steroids to have 
any adverse effects at that point in time (Table 1) 
Further studies are needed both in animals and in 
children before any conclusions can be made about 
impairment of alveolar development by inhaled 
steroids in children. 
Long-term growth 
Growth during childhood takes place in three phases. 
During the first two years, there is rapid, but deceler- 
ating growth, that is determined mainly by nutrition. 
Relatively steady childhood growth then follows that 
is regulated by the growth hormone axis, until the 
onset of puberty. The third phase, the pubertal 
growth spurt, is controlled by a combination of 
growth hormone and sex hormones. Slow prepubertal 
growth is a characteristic of asthma and appears to be 
independent of disease severity or treatment (6). 
Despite a reduction in growth rate, most children 
with asthma (possibly with the exception of those 
with very severe disease) attain a normal final height 
(7). A meta-analysis of the effects of oral and inhaled 
corticosteroids on growth concluded that final 
height is not affected by treatment with inhaled 
corticosteroids(8). 
Treatment with low-dose systemic steroids or high- 
dose inhaled steroids may result in decreased growth 
velocity, but as long as this is accompanied by a 
concomittant slowing in development of bone age, 
the child will eventually reach normal final height. 
Only if there is a greater effect on growth than on 
bone age, will there be a problem. 
When attempting to determine the effects of 
inhaled corticosteroids on growth, a large number of 
different factors have to be taken into account. For 
example, children with more severe asthma are likely 
to receive higher doses of inhaled corticosteroids, 
which will cause greater suppression of growth. How- 
ever, poorly controlled asthma itself is associated 
with stunting growth. Also, there may be seasonal 
factors, such as reduced growth over the Winter 
period which might appear to increase the suppressive 
effects of inhaled corticosteroids, since asthma is 
often less well controlled during Winter. A study of 
inhaled fluticasone propionate at doses of up to 
200,~glday for up to 52 weeks showed no adverse 
effect on growth in children (9). 
In conclusion, when the dose of inhaled cortico- 
steroid is tailored individually to the severity of the 
disease and an optimal delivery system is used, 
inhaled corticosteroids do not adversely affect lung 
development or long-term growth in paediatric 
asthma patients. 
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